Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma (R+Pirto in Newly Diagnosed MZL)
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Marginal Zone Lymphoma
DRUG: Pirtobrutinib
Objective response rate (ORR) defined as the proportion of subjects achieving a partial response (PR) or complete response (CR) by Lugano Criteria at Cycle 7., To assess the ORR in the study population at Cycle 7., 7 months
The proportion of subjects achieving a complete response (CR) by Lugano Criteria at Cycle 7., To assess the rate of CR in the study population., 7 months|Median and two year Progression-free survival (PFS). PFS will be as defined as the time from study drug initiation to the time of documented disease progression (as assessed by Lugano Criteria), or death from any cause., To assess PFS., 7 years|Duration of response (DoR), defined as the interval of time from the date of initial documented response (PR or better per Lugano Criteria) to the time of progression from the best response, the start of a new therapy, or death from any cause., To assess the DoR of the study population., 7 years|Median and two year overall survival (OS). OS is defined as the time from registration until death from any cause., To assess OS in this study population., 7 years
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.